Liefaard, M. C. http://orcid.org/0000-0002-3692-3566
van der Voort, A.
van Seijen, M.
Thijssen, B. http://orcid.org/0000-0003-1562-2649
Sanders, J.
Vonk, S.
Mittempergher, L. http://orcid.org/0000-0003-3425-3965
Bhaskaran, R.
de Munck, L. http://orcid.org/0000-0002-2930-509X
van Leeuwen-Stok, A. E.
Salgado, R. http://orcid.org/0000-0002-1110-3801
Horlings, H. M. http://orcid.org/0000-0003-4782-8828
Lips, E. H. http://orcid.org/0000-0003-3488-4935
Sonke, G. S.
Funding for this research was provided by:
Team Westland Foundation
Employee of Agendia at the time of data analysis.
Article History
Received: 28 July 2023
Accepted: 5 April 2024
First Online: 18 April 2024
Competing interests
: G.S.S. reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen and consultancy fees paid to the institute from Biovica and Seagen. H.M.H. reports institutional research support from Roche. A.E.v.L. reports institutional research support from Agendia, AstraZeneca, Daiichi, Lilly, Novartis and Roche. L.M and R.B. were employees of Agendia NV at the time of analysis. The remaining authors declare no competing interests.